• Modernized trial eligibility criteria aim to remove comorbidities as a barrier to enrollment

    5 monthes ago - By Healio

    Patients with cancer and comorbidities are routinely left out of clinical trial discussions, offers and participation, according to results of a study published in JAMA Oncology.
    At least 60% of trial eligibility exclusions are related to patient comorbidities or performance status, according to study background.
    Those statistics could start to change because of the implementation of new eligibility guidelines for clinical trials, due in part to this and other studies.
    “The movement to modernize eligibility criteria in trials has been led by both researchers and patient advocacy groups.
    Read more ...

     

  • Top stories in hematology/oncology: Bristol-Myers Squibb acquires Celgene, ASH initiates clinical trials for sickle cell disease therapies

    5 monthes ago - By Healio

    Among the top hematology/oncology stories last week were an announcement that Bristol-Myers Squibb will merge with Celgene, and a report that ASH launched sickle cell disease clinical trials to develop new therapies.
    Other highlights include a study that concluded stress is associated with poor outcomes in chronic lymphocytic leukemia, findings that suggested that topical agents do not increase radiation doses in cancer radiotherapy, and a report that announced an NCI grant will fund chimeric antigen receptor T-cell therapy for treatment of solid tumors.
    Bristol-Myers Squibb to acquire Celgene
    Read more ...